Insight

Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe

Photo from Kamran Ahmed/X

Aug 29, 2024, 16:48

Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe

JAMA Oncology shared a post on X about a recent paper by Kamran Ahmed et al. published in JAMA Oncology.

“Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: A Phase 1 Nonrandomized Controlled Trial”

Authors: Kamran Ahmed, Priya Kumthekar, Yolanda Pina, Youngchul Kim, Michael Vogelbaum, Hyo Han, Peter Forsyth

“Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging.”

Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers at the National Cancer Centre Singapore, shared this post, adding:

“Fascinating! With promising results for this group of very poor players.”

Source: JAMA Oncology/X and Melvin Chua/X

cancer HER2+ breast leptomeningeal disease Hyo Han JAMA Oncology Kamran Ahmed Melvin Chua Michael Vogelbaum National Cancer Centre Singapore OncoDaily Oncology pertuzumab Peter Forsyth Priya Kumthekar radiation therapy trastuzumab Yolanda Pina Youngchul Kim

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage